

PRESS-RELEASE – FOR IMMEDIATE RELEASE

Calmino and Ewopharma join up to treat Irritable Bowel Syndrome (IBS)

Schaffhausen, Switzerland, 29.04.22 - IBS affects 10-15% of the European population, but less than 2% are correctly diagnosed. Many individuals have been suffering for many years. IBS is a chronic disorder which strongly affects the quality of one's life. A group of symptoms occur together, including repeated abdominal pain and changes in bowel movements, which may be diarrhoea, constipation - or both. Other typical symptoms are bloating, distension, flatulence and borborygmi. As the main cause of IBS is not definitely known, treatment focuses on the symptoms.

PROIBS® - to help patients treat IBS symptoms

PROIBS® is a certified medical device for the treatment of IBS symptoms such as abdominal pain, bloating and unsettled bowel movements (diarrhoea and/or constipation). PROIBS® contains AVH200®, derived from the plant *Aloe barbadensis* Mill. AVH200® has gel forming components which support the intestinal mucosal barrier.

As IBS is known to affect individuals for a long period of time, it is essential to have a treatment appropriate for long-term use – as PROIBS® is. The product is safe, and no interactions with other medications are known.

Science-driven innovative Calmino group AB, the developer of PROIBS®, conducted a usability study among 1.003 users. PROIBS® was helpful for 94% of them. 91% of the users experienced an improvement in daily life and 98% would recommend PROIBS® to someone else. To learn more please check: www.proibs.eu.



Calmino group AB (Gothenburg, Sweden) and Ewopharma (Schaffhausen, Switzerland) have entered into an exclusive distribution agreement for the territories of Czech Republic and Slovakia in order to launch PROIBS® for the treatment of symptoms related to IBS. This agreement includes all marketing and sales activities of PROIBS® as of April 2022.

Simone Thomas, Senior Product Manager at Ewopharma Group comments: «With PROIBS®, we are able to provide an innovative and certified medical device for the treatment of symptoms related to IBS. The product has been on the Swedish pharmacy market for more than a decade. Because it is recommended by physicians and dietitians, we can promote PROIBS® with absolute confidence. We are looking forward to offering a solution that truly improves the liveability of the affected people.»

Tobias Kisker, CEO and founder of Calmino group AB, is pleased to start a long and successful collaboration with Ewopharma. «The Calmino team is happy to work with a well-established, experienced, and professional company like Ewopharma. We see the Czech Republic and Slovakia as a first important introduction to other Central Eastern European markets.»

Page 2 of 2

About Calmino AB

Calmino group AB is a Swedish, science-driven innovative healthcare company with focus on gut health. Their vision is to successfully contribute towards improving health and well-being for people with digestive and gastrointestinal disorders. Calmino was founded in 2003. In 2010, a product for the dietary management of IBS under the brand “PROIBS®” was launched. After many successful years on the market in various pharmacies in Sweden and other European countries, the product was recently certified as a medical device for the treatment of IBS symptoms. For more information visit www.calmino.com

About Ewopharma AG

Ewopharma AG, headquartered in Schaffhausen (Switzerland), is a pharmaceutical marketing company focused on Central Eastern Europe and Switzerland. With more than 60 years presence in the region, Ewopharma has extensive knowledge of these markets and enjoys a privileged position in the area. The company covers all aspects of market access and commercialisation of ethical pharmaceutical and consumer health products. Further information is available at www.ewopharma.com.

For further information, please contact:

Calmino group AB
Tobias Kisker
Founder and CEO
Tel.: +46 705 88 14 53
E-Mail: tobias.kisker@calmino.com

or

Ewopharma AG
Simone Thomas
Senior Product Manager Ewopharma Group
Tel.: +41 52 633 09 99
E-mail: s.thomas@ewopharma.com